All Stories

  1. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients
  2. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time
  3. Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy
  4. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
  5. Surgical Outcome of Laparoscopic Surgery, Including Laparoendoscopic Single-Site Surgery, for Retroperitoneal Paraganglioma Compared with Adrenal Pheochromocytoma
  6. Predictors of survival in patients with disease recurrence after radical nephroureterectomy
  7. Laparoendoscopic single-site adrenalectomy versus conventional laparoscopic adrenalectomy: a comparison of surgical outcomes and an analysis of a single surgeon’s learning curve
  8. Unidirectional barbed suture for vesicourethral anastomosis during laparoscopic radical prostatectomy
  9. MP28-04 AXL IS A NOVEL PROGNOSTIC MARKER IN UPPER URINARY TRACT UROTHELIAL CARCINOM
  10. MP21-13 THERAPEUTIC EFFECT BY TARGETING BCL-XL PROTEIN IN UROTHELIAL CARCINOMA CELLS
  11. MP34-01 NICOTINE INDUCES TUMOR AGGRESSIVENESS AND CHEMORESISTANCE THROUGH ACTIVATION OF PI3K/AKT/MTOR PATHWAY IN BLADDER CANCER
  12. MP56-04 IMPACT OF LYMPHOVASCULAR INVASION STATUS IN TRANSURETHRAL RESECTION OF BLADDER TUMORS COULD PREDICT SUBSEQUENT STAGE PROGRESSION IN T1 BLADDER TUMORS.
  13. MP24-10 DRUG EFFICACY REPROGRAMMING BY RIBAVIRIN AGAINST THE CANCER STEMNESS IN DOCETAXEL-RESISTANT PROSTATE CANCER
  14. MP21-11 UP-REGULATED NFκB ACTIVATION IS A POTENT THERAPEUTIC TARGET IN ACQUIRED PLATINUM-RESISTANT BLADDER CANCER: THE EFFICACY OF NFκB BLOCKADE BY DEHYDROXYMETHYL DERIVATIVE OF EPOXYQUINOMICIN (DHMEQ)
  15. MP29-02 INCREASED EXPRESSION OF ARYL HYDROCARBON RECEPTOR IN CLEAR CELL RENAL CELL CARCINOMA AND INFILTRATING LYMPHOCYTES: IMPLICATIONS FOR CANCER INVASION, PROGNOSIS AND TUMOR IMMUNITY
  16. MP52-20 POST-TRANSLATIONAL MODIFICATION MEDIATED BY THE PROLYL ISOMERASE PIN1 ACCERELATE CANCER PROGRESSION IN CASTRATION RESISTANT PROSTATE CANCER
  17. MP16-18 DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS
  18. MP24-14 METABOLIC SHIFT UNDER HYPOXIC ENVIRONMENT CAUSES RESISTANCE TO MTOR INHIBITOR IN HUMAN CASTRATION RESISTANT PROSTATE CANCER.
  19. MP32-11 ERECTILE FUNCTION IS HIGHLY ASSOCIATED WITH PROSTATE-SPECIFIC ANTIGEN BOUNCE IN LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
  20. MP70-03 OPTIMAL TIMING OF HORMONAL THERAPY FOR PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY
  21. PD23-11 PROSPECTIVE EVALUATION OF EFFICACY AND SAFETY OF SOLIFENACIN AND MIRABEGRON TREATMENT IN BPH PATIENTS TREATED WITH DUTASTERIDE BUT HAVING OAB SYMPTOMS
  22. MP39-14 METFORMIN IS A NEW THERAPEUTIC STRATEGY FOR TARGETING CD44 VARIANT IN BLADDER CANCER
  23. MP56-12 TIMING OF 1ST RECURRENCE AFFECTS SUBSEQUENT CLINICAL OUTCOME IN 1ST RECURRENT LOW GRADE TA BLADDER CANCER.
  24. MP77-07 IMPACT OF SMOKING STATUS AND CUMULATIVE EXPOSURE ON INTRAVESICAL RECURRENCE OF UPPER TRACT UROTHELIAL CARCINOMA AFTER RADICAL NEPHROURETERECTOMY
  25. MP77-19 THE PREDICTIVE VALUE OF C-REACTIVE PROTEIN FOR PROGNOSIS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH CISPLATIN-BASED CHEMOTHERAPY FOLLOWING RADICAL NEPHROURETERECTOMY: MULTI-INSTITUTIONAL STUDY
  26. Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma
  27. Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates
  28. Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression
  29. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
  30. The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional Study
  31. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study
  32. Visceral Fat Is Correlated With Prolonged Operative Time in Laparoendoscopic Single-site Adrenalectomy and Laparoscopic Adrenalectomy
  33. Periprostatic Fat Area Is an Independent Factor That Prolonged Operative Time in Laparoscopic Radical Prostatectomy
  34. Effect of a Novel Nuclear Factor-κB Activation Inhibitor on Renal Ischemia-Reperfusion Injury
  35. Editorial Comment to Template‐based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study
  36. Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location
  37. C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy
  38. Abdominal Wall
  39. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
  40. Impact of Smoking Status on Bladder Tumor Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
  41. Efficacy and safety of gemcitabine monotherapy in an elderly patient with penile metastasis from bladder carcinoma: a case report
  42. 506 INTRACRINE DYNAMICS OF CYP17A1 ACTIVITIES IN HUMAN CASTRATION RESISTANT PROSTATE CANCER
  43. 1318 HYPOXIC MICROENVIRONMENT PROMOTES PI3K/AKT/MTOR SIGNALING PATHWAYS IN HUMAN CASTRATION RESISTANT PROSTATE CANCER
  44. How Can Lymphocele Development Be Prevented After Laparoscopic Radical Prostatectomy?
  45. 897 IMPACT OF SMOKING STATUS ON BLADDER RECURRENCE FOLLOWING RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
  46. 649 COLOR DOPPLER SONOGRAPHIC EVALUATION OF URETERIC JET ANGLE IN DETECTING HIGH GRADE VESICOURETERAL REFLUX IN INFANTS AND YOUNG CHILDREN
  47. 240 PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY BY CLINICOPATHOLOGICAL FACTORS: SUITABILITY OF MAGNETIC RESONANCE IMAGING
  48. 51 LAPAROSCOPIC ADRENALECTOMY INCLUDING LESS IN PATIENTS WITH PHEOCHROMOCYTOMA: THE EVALUATION OF PERIOPERATIVE SURGICAL RISK
  49. 1165 NOVEL ALGORITHM FOR PREDICTING SEVERE CASES OF ACUTE BACTERIAL PROSTATITIS
  50. 698 PROGNOSTIC SIGNIFICANCE OF BCL-XL PROTEIN EXPRESSION ON SURVIVAL IN PATENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH RADICAL NEPHROURETERECTOMY
  51. 700 THE PROGNOSTIC SIGNIFICANCE OF VASOHIBIN-1 EXPRESSION IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA
  52. 584 THERAPEUTIC EFFECT OF INTRAVESICAL ADMINISTRATION OF A NOVEL NANOTRANSPORTER FOR PACLITAXEL IN AN ORTHOTOPIC BLADDER CANCER MODEL
  53. 1951 OBSTRUCTIVE SLEEP APNEA SYNDROME SHOULD BE CONSIDERED AS ONE OF CAUSES FOR NOCTURIA IN YOUNGER PATIENTS WITHOUT OTHER VOIDING SYMPTOM
  54. 2197 BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER; TO PERFORM OR NOT?: EXTERNAL VALIDATION OF THE CURRENTLY AVAILABLE GUIDELINES FOR JAPANESE PATIENTS
  55. 1788 THE RELATIONSHIP BETWEEN RENIN-ANGIOTENSIN SYSTEM BLOCKADE AND TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER
  56. 672 UNDETECTABLE TUMOR THROUGH PREOPERATIVE MRI PREDICTS ORGAN CONFINED DISEASE AND LOWER TUMOR VOLUME IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER
  57. 1787 DIHYDROPYRIMIDINE DEHYDROGENASE IS ASSOCIATED WITH CLINICAL OUTCOME IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
  58. 310 MTOR PATHWAY REGULATES THE EXPRESSION OF ANGIOTENSIN 2 TYPE 1 RECEPTOR IN RENAL CELL CARCINOMA
  59. 1782 SHOULD A FIRST RECURRENT LOW GRADE TA BLADDER CANCER BE MANAGED AS AN INTERMEDIATE-RISK GROUP TUMOR?
  60. 1781 IS IT NECESSARY TO ROUTINELY PERFORM MULTIPLE BIOPSIES FROM NORMAL-APPEARING UROTHELIUM WHEN URINE CYTOLOGY IS POSITIVE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER?
  61. 398 CHARACTERISTICS AND OUTCOME IN METASTATIC UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL EXPERIENCE
  62. 973 A NEW STRATEGY FOR CASTRATION RESISTANT PROSTATE CANCER WITH TARGETING TO FEEDBACK MECHANISM OF PI3K/AKT/MTOR PATHWAY
  63. 681 THE DISTINCT ASSOCIATION BETWEEN PRIMARY TUMOR LOCATION AND THE PATTERNS OF METASTATIC SPREAD FOLLOWING RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
  64. 697 C-REACTIVE PROTEIN INDEPENDENTLY PREDICTS THE PROGNOSIS OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH RADICAL NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL STUDY
  65. 399 PREDICTIVE VALUE OF POSITIVE URINE CYTOLOGY FOR PROGNOSIS IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY
  66. A Prospective Longitudinal Survey of Erectile Dysfunction in Patients with Localized Prostate Cancer Treated with Permanent Prostate Brachytherapy
  67. Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
  68. Risk Factors for Perioperative Complications of Laparoscopic Adrenalectomy Including Single-Site Surgery
  69. Metastatic urothelial carcinoma to pericardia manifested by dyspnea from cardiac tamponade during systemic chemotherapy: Case report and literature review
  70. What is the predictor of prolonged operative time during laparoscopic radical prostatectomy?
  71. Does laparoendoscopic single-site adrenalectomy increase surgical risk in patients with pheochromocytoma?
  72. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma
  73. Does Pelvic Lymph Node Dissection Improve the Biochemical Relapse-Free Survival in Low-Risk Prostate Cancer Patients Treated by Laparoscopic Radical Prostatectomy?
  74. Reply
  75. Prognostic Value of Renin–Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer
  76. Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification
  77. Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma
  78. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy
  79. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma
  80. Renal cell carcinoma arising from a horseshoe kidney in a chronic hemodialysis patient
  81. Visceral obesity is a strong predictor of perioperative outcome in patients undergoing laparoscopic radical nephrectomy
  82. Transumbilical laparoendoscopic single-site partial nephrectomy using a microwave tissue coagulator
  83. Risk of subsequent tumour recurrence and stage progression in bacille Calmette‐Guérin relapsing non‐muscle‐invasive bladder cancer
  84. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy
  85. 392 DISEASE-FREE SURVIVAL AS A SURROGATE FOR 5-YEAR OVERALL SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA
  86. 386 PROGNOSTIC VALUE OF PLASMA FIBRINOGEN LEVELS IN PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA
  87. 969 PI3K/AKT DUAL INHIBITOR RESTORES DOCETAXEL SENSITIVITY IN CASTRATION RESISTANT PROSTATE CANCER
  88. 963 HOW DOES 5α-REDUCTASE ACTIVITY CHANGE DURING THE PROGRESSION OF CASTRATION RESISTANT PROSTATE CANCER?
  89. 965 LONG-TERM ANDROGEN ABLATION AND TREATMENT WITH TAXANES UP-REGULATE PHOSPHORYLATED AKT IN CASTRATION RESISTANT PROSTATE CANCER
  90. 968 REGULATION OF MCP-1 EXPRESSION THROUGH ANGIOTENSIN II TYPE 1 RECEPTOR IN CASTRATION-RESISTANT PROSTATE CANCER
  91. 50 THE VISCERAL TYPE OF ADIPOSE ACCUMULATION PREDICTS POTENTIAL TECHNICAL DIFFICULTIES WHEN PERFORMING LAPAROSCOPIC ADRENALECTOMY
  92. 2193 PREOPERATIVE GRADING OF HYDRONEPHROSIS CAN IMPROVE THE ACCURACY OF WORSE PATHOLOGICAL PREDICTION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED SURGICALLY
  93. 1150 A PROSPECTIVE LONGITUDINAL SURVEY OF ERECTILE DYSFUNCTION RATE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
  94. 556 NOVEL NF-KAPPAB INHIBITOR DHMEQ: THE NEW STRATEGY FOR ACQUIRED CHEMO-RESISTANT BLADDER CANCER
  95. 609 COLOR DOPPLER SONOGRAPHIC EVALUATION OF URETERIC JET ANGLE IN DETECTING HIGH GRADE VESICOURETERAL REFLUX IN CHILDREN
  96. 880 ACQUIRED PLATINUM RESISTANCE INDUCES ANGIOGENIC AGGRESSIVENESS THROUGH UPREGULATION OF ANGIOTENSIN II TYPE 1 RECEPTORS IN BLADDER CANCER
  97. 307 BISEBROMOAMIDE, AS A NOVEL MOLECULAR TARGET DRUG INHIBITING PHOSPHORYLATION OF BOTH EXTRACELLULAR SIGNAL-REGULATED KINASE AND AKT IN RENAL CELL CARCINOMA
  98. 1019 THERAPEUTIC EFFECT AFTER TRANSUMBILICAL LAPAROSCOPIC SINGLE-SITE ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM: A MATCHED CASE-CONTROL STUDY
  99. 1766 THE CLINICAL FEATURE OF WORSENING PROGRESSION IN PATIENTS WITH PTA NON-MUSCLE INVASIVE BLADDER TUMORS
  100. 1768 CLINICAL SIGNIFICANCE OF THE CLASSIFICATION FOR BACILLUS CALMETTE-GUÉRIN FAILURE IN NON-MUSCLE INVASIVE BLADDER CANCERS
  101. 637 PREOPERATIVE T STAGING AND PREDICTION OF HISTOPATHOLOGIC GRADING OF UROTHELIAL CARCINOMA IN RENAL PELVIS USING DIFFUSION-WEIGHTED MRI
  102. 1142 A PROSPECTIVE STUDY OF THE EFFECT OF 5-ALPHA-REDUCTASE INHIBITOR (DUTASTERIDE) TREATMENT ON SERUM FREE TESTOSTERONE LEVEL AND AGING MALE SYMPTOMS IN JAPANESE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
  103. Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
  104. Regulation of Monocyte Chemoattractant Protein-1 Through Angiotensin II Type 1 Receptor in Prostate Cancer
  105. Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma
  106. Prognostic significance of Bacillus Calmette‐Guérin failure classification in non‐muscle‐invasive bladder cancer
  107. The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy
  108. Three cases of granulocyte colony-stimulating factor-producing urinary upper tract carcinomas
  109. Transumbilical approach for laparo‐endoscopic single‐site adrenalectomy: Initial experience and short‐term outcome
  110. Surgical and Chemotherapeutic Options for Urachal Carcinoma: Report of Ten Cases and Literature Review
  111. Intravesical Interleukin-15 Gene Therapy in an Orthotopic Bladder Cancer Model
  112. Preoperative T Categorization and Prediction of Histopathologic Grading of Urothelial Carcinoma in Renal Pelvis Using Diffusion-Weighted MRI
  113. Radiological findings of primary localized amyloidosis of the ureter
  114. Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience
  115. Extrapancreatic solid pseudopapillary tumor: case report and review of the literature
  116. Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer
  117. Preoperative Hydronephrosis Grade Independently Predicts Worse Pathological Outcomes in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Carcinoma
  118. Comparison of CT Urography and Excretory Urography in the Detection and Localization of Urothelial Carcinoma of the Upper Urinary Tract
  119. The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes After Radical Nephrouretectomy for Upper Urinary Tract Urothelial Carcinoma
  120. Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer
  121. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study
  122. Angiotensin II Type 1 Receptor Expression and Microvessel Density in Human Bladder Cancer
  123. 1061 ACTIVATION OF THE ARYL HYDROCARBON RECEPTOR PATHWAY ENHANCES CANCER CELL INVASION BY UP-REGULATING THE MMP EXPRESSION IN UROTHELIAL CANCER
  124. 364 THE CORRELATION OF CLASSIC CADHERINS WITH CLINICOPATHOLOGICAL FACTORS IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA
  125. 517 INTRAVESICAL LIPOSOME-MEDIATED INTERLEUKIN-15 GENE THERAPY ENHANCES TUMOR-SPECIFIC CYTOTOXICITY IN ORTHOTOPIC MURINE BLADDER CANCER MODEL
  126. 28 THE VISCERAL TYPE OF ADIPOSE ACCUMULATION PREDICTS POTENTIAL TECHNICAL DIFFICULTIES WHEN PERFORMING LAPAROENDOSCOPIC SINGLE-SITE ADRENALECTOMY
  127. 1284 LOW DOSE DOCETAXEL ENHANCES THE SENSITIVITY OF S-1 IN A XENOGRAFT MODEL OF HUMAN CASTRATION RESISTANT PROSTATE CANCER
  128. 1373 THE NOVEL NF-κB ACTIVATION INHIBITORDEHYDROXYMETHYL-EPOXYQUINOMICIN SUPPRESSES NON-IMMUNE AND IMMUNE INFLAMMATORY KIDNEY DISEASE IN RATS
  129. 1069 CLINICAL SIGNIFICANCE OF SNAIL EXPRESSION IN BLADDER TUMOR AND ITS HYPOXIC REGULATION
  130. 1052 DOES NF-KB ACTIVATION INHIBITOR, DHMEQ OVERCOME THE CHEMORESISTANCE TO CISPLATIN IN BLADDER CANCER?
  131. 1356 METASTIN, THE FINAL PEPTIDE OF KISS-1 GENE, PREVENTS LUNG METASTASES OF MURINE BLADDER CANCER
  132. 1739 FREQUENCY OF TUMOR RECURRENCE: A STRONG PREDICTOR OF STAGE PROGRESSION IN INITIALLY DIAGNOSED NONMUSCLE INVASIVE BLADDER CANCER
  133. 1741 COULD PATIENT AGE INFLUENCE TUMOR RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH BCG IMMUNOTHERAPY?
  134. 1748 ANGIOTENSIN II TYPE 1 RECEPTOR AND MICROVESSEL DENSITY PREDICT THE EARLY INTRAVESICAL RECURRENCE IN BLADDER CANCER
  135. 1265 PROGNOSTIC SIGNIFICANCE OF HIGH NUCLEAR GRADE FOR PATIENTS WITH PATHOLOGIC T1A RENAL CELL CARCINOMA
  136. 1059 REACTIVE OXYGEN SPECIES GENERATION INCREASED BY CIS-DICHLORODIAMMINEPLATINUM ENHANCES VEGF PRODUCTION THROUGH UPREGULATING ANGIOTENSIN II TYPE 1 RECEPTOR IN BLADDER CANCER
  137. 1211 DOES LAPAROENDOSCOPIC SINGLE-SITE ADRENALECTOMY INCREASE SURGICAL RISK IN PATIENTS WITH UNILATERAL PHEOCHROMOCYTOMA?; CASE CONTROL STUDY
  138. 901 PREDICTION AND STRATIFICATION OF THE DEVELOPMENT OF URINARY RETENTION IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER TREATED WITH HORMONE THERAPY
  139. 664 PROGNOSTIC SIGNIFICANCE OF 5-FLUOROURACIL METABOLISM-RELATING ENZYMES IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA
  140. 1388 THE IMPACT OF PREVIOUS URETEROSCOPIC TUMOR ABLATION ON ONCOLOGIC OUTCOMES AFTER RADICAL NEPHROURETECTOMY FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA
  141. Urinary pH Is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor
  142. Upper urinary tract urothelial carcinoma with loco‐regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration
  143. Phosphorylated Akt up‐regulates angiotensin II type‐1 receptor expression in castration resistant prostate cancer
  144. Frequency of Tumor Recurrence: A Strong Predictor of Stage Progression in Initially Diagnosed Nonmuscle Invasive Bladder Cancer
  145. Reply by the Authors
  146. Renal Cell Carcinoma Accompanied by Left-sided IVC
  147. PROSPECTIVE SURVEY OF ERECTILE DYSFUNCTION AFTER EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER
  148. 膀胱全摘術後9年目に残存尿道および鼡径リンパ節へ再発した膀胱癌の1例
  149. Technical difficulties of transumbilical laparoendoscopic single-site adrenalectomy: comparison with conventional laparoscopic adrenalectomy
  150. Initial experience of transumbilical laparoendoscopic single-site surgery of partial adrenalectomy in patient with aldosterone-producing adenoma
  151. Cancer death from non‐muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999–2001 registry in Japan
  152. How Do Young Residents Practice Laparoscopic Surgical Skills?
  153. Regulation of human dendritic cells by a novel specific nuclear factor–κB inhibitor, dehydroxymethylepoxyquinomicin
  154. Characteristics and management of erectile dysfunction after various treatments for prostate cancer
  155. Fifth Joint Meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association
  156. Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study
  157. Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature
  158. Reply
  159. Late Recurrence and Progression in Non-muscle–invasive Bladder Cancers After 5-year Tumor-free Periods
  160. Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy
  161. Advanced patient age is associated with inferior cancer‐specific survival after radical nephroureterectomy
  162. The clinical significance of urine cytology after a radical cystectomy for urothelial cancer
  163. 229 HOW DOES ETS FAMILY CONTRIBUTE TO PROSTATE CANCER PROGRESSION?
  164. 976 CIS-DICHLORODIAMMINEPLATINUM UPREGULATES THE EXPRESSION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ AND ENHANCES THE CYTOTOXICITY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ AGONIST
  165. 1357 LATE RECURRENCE AND PROGRESSION IN NON-MUSCLE INVASIVE BLADDER CANCERS AFTER 5-YEAR TUMOR-FREE PERIODS: CAN EXISTING RISK STRATIFICATION PROVIDE ACCURATE ESTIMATES OF LATE RECURRENCE AND PROGRESSION?
  166. 301 THE IMPACT OF POSITIVE CORE DENSITY ON PREDICTION OF THE PRETREATMENT STAGE OF PROSTATE CANCER
  167. 421 UPPER URINARY TRACT UROTHELICAL CARCINOMA WITH LOCOREGIONAL NODAL METASTASES: EXPERIENCE WITH AGGRESSIVE INTEGRATION OF SYSTEMIC THERAPY FOLLOWED BY RADICAL NEPHROURETERECTOMY
  168. 969 NOVEL THERAPEUTIC MODALITY OF S-1 IN COMBINATION WITH CPT-11 TO OVERCOME 5-FLUOROURACIL RESISTANCE IN BLADDER CANCER
  169. 980 VITAMIN E DERIVATIVES IN COMBINATION WITH ANTICANCER DRUGS FOR BLADDER CANCER CELLS: NF-κB IS A KEY MOLECULE FOR THE SYNERGISTIC EFFECTS OF α-TOCOPHEROL SUCCINATE AND PACLITAXEL
  170. 558 FUNCTIONAL ANALYSIS OF MIRNA IN TUMOR MICROENVIRONMENT AS A KEY REGULATOR OF AGGRESSIVE ANGIOGENESIS OF HORMONE-REFRACTORY PROSTATE CANCER
  171. 1465 CONSERVATIVE THERAPY FOR BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: FOR WHOM SHOULD CYSTECTOMY BE CONSIDERED?
  172. 784 SYNERGISTIC THERAPEUTIC EFFECT OF NF-κB AND AP-1 FUNCTION INHIBITORS ON SUPPRESSION OF CELL GROWTH AGAINST HIGHLY AGGRESSIVE BLADDER CANCER CELLS
  173. 787 CIS-DICHLORODIAMMINEPLATINUM UPREGULATES ANGIOTENSIN TYPE 1 RECEPTOR AND ENHANCES THE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED BY ANGIOTENSIN II
  174. 218 DOWN-REGULATION OF MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE-1 EXPRESSION PREDICTS FOR POOR SURVIVAL IN RENAL CELL CARCINOMA
  175. Potent Cytotoxic Effect of a Novel Nuclear Factor-κB Inhibitor Dehydroxymethylepoxyquinomicin on Human Bladder Cancer Cells Producing Various Cytokines
  176. Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract
  177. Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient
  178. Predicting the probability of significant prostate cancer in Japanese men with serum prostate‐specific antigen less than 10 ng/mL: Development of a novel pre‐biopsy nomogram
  179. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo
  180. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
  181. Are predictive models for cancer volume clinically useful in localized prostate cancer?
  182. Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer
  183. Tumour length of the largest focus predicts prostate‐specific antigen‐based recurrence after radical prostatectomy in clinically localized prostate cancer
  184. Renal Damage Inhibited in Mice Lacking Angiotensinogen Gene Subjected to Unilateral Ureteral Obstruction
  185. Ets‐1 and hypoxia inducible factor‐1α inhibition by angiotensin II type‐1 receptor blockade in hormone‐refractory prostate cancer
  186. The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?
  187. Discontinuance of Bacille Calmette-Guérin Instillation Therapy for Nonmuscle-invasive Bladder Cancer Has Negative Effect on Tumor Recurrence
  188. Brain metastasis of a papillary renal cell carcinoma, identified as type 2
  189. Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy
  190. Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
  191. ROLE OF ESTROGENS IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
  192. FUNCTIONAL ANALYSIS OF SNAIL IN BLADDER CANCER: A KEY TRANSCRIPTIONAL FACTOR OF EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)
  193. INTRAVESICAL INTERLEUKIN-15 GENE THERAPY IN A MOUSE ORTHOTOPIC BLADDER CANCER MODEL
  194. MR BLOCKADE IN RENAL CELL CARCINOMA REVEALED TUMOR SUPPRESSION THROUGH ENDOPLASMIC RETICULUM STRESS-INDUCED APOPTOSIS
  195. DISCONTINUANCE OF BCG INSTILLATION THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER HAS A NEGATIVE IMPACT ON TUMOR RECURRENCE
  196. OPTIMIZED URINARY PH IS NECESSARY FOR THE IMPROVEMENT OF ADJUVANT MMC INSTILLATION TREATMENT FOR TUMOR RECURRENCE OF NON-MUSCLE INVASIVE BLADDER TUMORS
  197. PSA CUT-OFF NOMOGRAM THAT AVOID OVER-DETECTION OF PROSTATE CANCER IN ELDERLY MEN
  198. ELEVATED EXPRESSION OF ARYL HYDROCARBON RECEPTOR IN RENAL CELL CARCINOMA IS ASSOCIATED WITH CIGARETTE SMOKE AND THE PROGNOSIS
  199. ETS-1 AND HYPOXIA INDUCIBLE FACTOR-1 α INDUCED BY ANGIOTENSIN II: NOVEL NEW MOLECULAR TARGETS OF ANGIOTENSINII TYPE-1 RECEPTOR BLOCKER (ARB) AS AN ANGIOGENIC INHIBITOR
  200. PROGNOSTIC SIGNIFICANCE OF SNAIL EXPRESSION IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA (UUT-UC)
  201. DEVELOPMENT OF PROGNOSTIC MODELS FOR INDIVIDUAL RISK STRATIFICATION IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY: A NEW TOOL TO HELP WITH PATIENT SELECTION FOR ADJUVANT THERAPY
  202. TUMOR NECROSIS IS AN INDICATOR OF AGGRESSIVE BIOLOGY IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
  203. AN ASSESSMENT OF THE MOST SIGNIFICANT DETERMINANTS OF THE NATURAL HISTORY OF UPPER TRACT TRANSITIONAL CELL CARCINOMA AFTER NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL RECURSIVE PARTITIONING MODEL
  204. REMOVAL OF AT LEAST 8 NODES IMPROVES CANCER-SPECIFIC SURVIVAL IN NON METASTATIC PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
  205. LAPAROSCOPIC NEPHROURETERECTOMY DOES NOT UNDERMINE CANCER CONTROL OUTCOMES IN SELECTED PATIENTS WITH NON-METASTATIC UPPER TRACT UROTHELIAL CARCINOMA
  206. PROPOSAL FOR SUBCLASSIFICATION OF PT3 UROTHELIAL CANCER OF THE RENAL PELVIS
  207. Angiotensin II Type 1 Receptor Antagonist Enhances Cis-dichlorodiammineplatinum-Induced Cytotoxicity in Mouse Xenograft Model of Bladder Cancer
  208. Clinical outcome of tumor recurrence for Ta, T1 non‐muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association
  209. Preoperative Prognostic Nomogram (Probability Table) for Renal Cell Carcinoma Based on TNM Classification
  210. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
  211. Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study
  212. Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association
  213. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy
  214. Carcinoma in situ of the Upper Urinary Tract Treated with Radical Nephroureterectomy – Results from a Multicenter Study
  215. Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments
  216. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer
  217. ENHANCED CHEMOSENSITIVITY TO PACLITAXEL BY VITAMIN E SUCCINATE IN BLADDER CANCER
  218. NUCLEAR EXPRESSION OF ARYL HYDROCARBON RECEPTOR PREDICTS DISEASE SPECIFIC SURVIVAL OF UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
  219. THE THERAPEUTIC EFFECTS OF THE HUMAN INTERLEUKIN-6 RECEPTOR ANTIBODY (TOCILIZUMAB) ON PROSTATE CANCER
  220. LONG-TERM OUTCOME OF RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER: BCG INSTILLATION IS NOT SUFFICIENTLY EFFECTIVE FOR LOW RISK PATIENTS
  221. RENAL INTERSTITIAL FIBROSIS, TUBULAR APOPTOSIS, AND INFLAMMATORY RESPONSE ARE INHIBITED IN MICE LACKING THE ANGIOTENSINOGEN GENE AND SUBJECTED TO UNILATERAL URETERAL OBSTRUCTION
  222. LYMPHOVASCULAR INVASION IS INDEPENDENTLY ASSOCIATED WITH CANCER RECURRENCE AND SURVIVAL IN PATIENTS WITH NEGATIVE LYMPH NODES AT RADICAL NEPHROURETERECTOMY
  223. TUMOR ARCHITECTURE IS AN INDEPENDENT PROGNOSTIC FACTOR FOR DISEASE RELAPSE AND CANCERSPECIFIC SURVIVAL IN PATIENTS TREATED WITH NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL ANALYSIS OF 1363 PATIENTS FROM THE UPPER TRACT UROTHELIAL CARCINOMA COLLABORATION
  224. OUTCOMES OF RADICAL NEPHROURETERECTOMY FOR UROTHELIAL CARCINOMA: A CONTEMPORARY SERIES FROM THE UPPER TRACT UROTHELIAL CARCINOMA COLLABORATION
  225. IMPACT OF TUMOR LOCATION ON PROGNOSIS FOR UPPER- TRACT UROTHELIAL CARCINOMA: OUTCOMES FROM OVER 1300 PATIENTS
  226. MORE EXTENSIVE LYMPHADENECTOMY IMPROVES THE PROGNOSIS OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA WITHOUT NODAL METASTASES
  227. ADJUVANT CHEMOTHERAPY FOR UPPER TRACT TRANSITIONAL CELL CARCINOMA: RESULTS FROM THE UPPER TRACT UCC CONSORTIUM
  228. Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients
  229. Simple Stratification of Survival Using Bone Scan and Serum C-Reactive Protein in Prostate Cancer Patients with Metastases
  230. Clinical Implications of Tumor Size and Local Extent of Primary Prostatic Lesions in Prostate Cancer Patients with Metastases: Value of Endorectal Magnetic Resonance Imaging in Patients with Metastases
  231. Carcinoma In Situ Developing in an Ileal Neobladder
  232. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer
  233. Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer
  234. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer
  235. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer
  236. LYMPHOVASCULAR INVASION INDEPENDENTLY PREDICTS INCREASED DISEASE SPECIFIC SURVIVAL IN PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE UPPER URINARY TRACT
  237. HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA
  238. IS TUMOR VOLUME AN INDEPENDENT PROGNOSTIC FACTOR IN CLINICALLY LOCALIZED PROSTATE CANCER?
  239. Detection and Quantitative Analysis of Early Stage Orthotopic Murine Bladder Tumor Using In Vivo Magnetic Resonance Imaging
  240. Enhancement of Diethylstilbestrol Induced Cytotoxicity by Bcl-2 Antisense Oligodeoxynucleotides and A Glutathione Depletor for Prostate Cancer
  241. Enhancement of Diethylstilbestrol Induced Cytotoxicity by Bcl-2 Antisense Oligodeoxynucleotides and A Glutathione Depletor for Prostate Cancer
  242. Prostate specific antigen adjusted for transition zone volume
  243. Percutaneous Endoscopic Marsupialization of a Pyelocaliceal Diverticulum with Milk ofCalcium Stones